Moreover, in translational trials for CRC therapy, antagonists of the CXCR4/CXCR7/CXCL12 axis need to be investigated in combination with chemotherapy, angiogenesis inhibitors, or immunotherapy. The gene discussed is CXCL12; the disease is colorectal carcinoma.